Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?

CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions that might otherwise be difficult to treat. The company already has a promising approved therapy in Casgevy, which regulators first approved in 2023 to treat patients with sickle cell disease. It has also obtained approval as a treatment for transfusion-dependent beta thalassemia. Will AI create the world's fir ...